Cargando…
MG132 protects against renal dysfunction by regulating Akt-mediated inflammation in diabetic nephropathy
Diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD). To date, mounting evidence has shown that inflammation may contribute to the pathogenesis of DN. Recent reports have shown that proteasome inhibitors display cytoprotection by reducing the phosphorylation of Akt, a serin...
Autores principales: | Zeng, Wei, Qi, Wei, Mu, Jiao, Wei, Yi, Yang, Li-Ling, Zhang, Qian, Wu, Qiong, Tang, Jian-Ying, Feng, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375942/ https://www.ncbi.nlm.nih.gov/pubmed/30765727 http://dx.doi.org/10.1038/s41598-018-38425-2 |
Ejemplares similares
-
The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro
por: Huang, Wei, et al.
Publicado: (2014) -
MG132 Ameliorates Kidney Lesions by Inhibiting the Degradation of Smad7 in Streptozotocin-Induced Diabetic Nephropathy
por: Gao, Chenlin, et al.
Publicado: (2014) -
Proteasome inhibitor MG132 inhibits the process of renal interstitial fibrosis
por: Han, Lin, et al.
Publicado: (2019) -
MG132 protects against lung injury following brain death in rats
por: Shi, Huijuan, et al.
Publicado: (2022) -
Prevention of Streptozotocin-Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IκB
por: Kong, Lili, et al.
Publicado: (2017)